环硅酸锆钠(Sodium Zirconium Cyclosilicate) - 药物靶点：Potassium_在研适应症：高钾血症，心脏衰竭_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Sodium zirconium cyclosilicate (USAN)、Sodium Zirconium Cyclosilicate Hydrate、Sodium zirconium cyclosilicate hydrate (JAN)

+ [12]

靶点

Potassium

作用方式

调节剂

作用机制

Potassium 调节剂(钾调节剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

阿斯利康制药有限公司AstraZeneca ABAstraZeneca Pharmaceuticals LP

+ [3]

非在研机构

Sharp Packaging Solution Corp.Zs Texas Ltd

ZS Pharma, Inc.

权益机构

ZS Pharma, Inc.

AstraZeneca PLC

最高研发阶段批准上市

首次获批日期

欧盟 (2018-03-22),

高钾血症

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

分子式H6NaO9Si3Zr

InChIKeyCRPYBEMVXUQTSH-UHFFFAOYSA-N

CAS号17141-74-1

关联

49

项与环硅酸锆钠相关的临床试验

NCT06736184

/ Not yet recruiting临床4期IIT

A Prospective Multicenter Randomized Controlled Trial on the Cardioprotective Effects of Improving Potassium Variability in Maintenance Hemodialysis Patients

The management of serum potassium in maintenance hemodialysis（MHD ）patients is one of the hot topics at present. In order to control hyperkalemia in dialysis patients, the use of hypokalemic dialysate is the most important measure to reduce potassium. This measure effectively reduces serum potassium, but increases the risk of hypokalemia after dialysis, which increases the risk of all-cause death in patients. Hyperkalemia and hypokalemia during and at the end of dialysis are important factors for arrhythmia and death in MHD patients. Due to the intermittent nature of hemodialysis treatment, MHD patients often experience frequent fluctuations in serum potassium, which is a potential risk factor for poor prognosis of MHD patients. Serum potassium variability can better reflect the potassium homeostasis in MHD patients. In addition to hyperkalemia and hypokalemia, serum potassium variability is a potential risk factor affecting the prognosis of MHD patients. At present, there are few studies on the effect of improving serum potassium variability on cardiovascular complications, especially multi-center randomized controlled trials. In this study, sodium zirconium cyclosilicate was used to control hyperkalemia before dialysis and increase potassium concentration in dialysate, so as to reduce the risk of hypokalemia after dialysis, and to verify whether improving serum potassium variability can reduce myocardial injury in hemodialysis patients.

开始日期2025-03-01

申办/合作机构

山东第一医科大学第一附属医院（山东省千佛山医院、山东省牙病防治指导中心）

NCT06578078

/ Recruiting临床3期IIT

A Randomized Clinical Trial to Define the Best Strategy for the Management of Heart Failure and Chronic Kidney Disease Among Elderly Patients With or at High Risk of hyperKalemia in Span by Optimizing the Use of RAASi With SZC

Heart failure (HF) and Chronic Kidney Disease (CKD) patients are frequently not administered renin-angiotensin aldosterone system inhibitor (RAASi) therapies at recommended doses due to hyperkalaemia, despite proven mortality and morbidity benefits. Sodium zirconium cyclosilicate (SZC) is a nonabsorbed potassium binder proven to lower serum potassium (S-K) and maintain normokalaemia. The purpose is to assess if a treatment regimen containing SZC will allow RAASi therapies to be optimized to target doses in patients with heart failure, chronic kidney disease and elevated serum potassium or at risk of developing elevated serum potassium.

开始日期2024-10-03

申办/合作机构-

IRCT20130313012810N11

/ SuspendedN/AIIT

Comparative bioequivalence study of sodium zirconium cyclosilicate (SZC-9) in the forms of 5 and 10 g sachets vs brand medicine (Lokelma made by AztraZeneca)

开始日期2024-08-31

申办/合作机构

Tabriz University of Medical Sciences

100 项与环硅酸锆钠相关的临床结果

登录后查看更多信息

100 项与环硅酸锆钠相关的转化医学

登录后查看更多信息

100 项与环硅酸锆钠相关的专利（医药）

登录后查看更多信息

283

项与环硅酸锆钠相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice

Article

作者: Mongelli, Valentina ; Merlo, Andrea ; Degli Esposti, Luca ; Maurizi, Anna Rita ; Cosentino, Nicola ; Leogrande, Melania ; Nugnes, Marta ; Gnesi, Marco ; Daniel, Francesca

AIMS:

Hyperkalemia (HK) is prevalent in patients with chronic kidney disease (CKD) and heart failure, particularly those on renin-angiotensin-aldosterone system inhibitors (RAASi). However, HK treatment often necessitates RAASi discontinuation. Sodium zirconium cyclosilicate (SZC), reimbursed in Italy since 2021, offers a new treatment option for HK. This study aimed to assess real-world SZC use and resulting economic rebounds in Italy.

METHODS:

Using administrative databases of healthcare entities covering about 6 million residents, patients with at least one prescription of SZC from Jan-2022 to Jun-2023 were identified. Patients receiving other potassium binders after SZC initiation were excluded. A logistic regression model estimated odds ratios (OR) with 95% confidence interval (95%CI) for predictors of long-term SZC use (>90 days), including age, sex, CKD status, and comorbidities. Univariate regression identified the potential association between each individual predictor and the likelihood of long-term treatment, followed by multivariate analysis adjusted for confounders. A backward stepwise logistic regression method retained only significant predictors, enhancing model accuracy.

RESULTS:

The study identified 355 SZC-treated patients (mean age 70.4 years, 64.2% male). CKD was found in 69.3% (47.6% on dialysis), with common comorbidities including hypertension (57.5%), diabetes (43.4%), and heart failure (23.4%). RAASi use was observed in 68.7% before SZC initiation, and RAASi discontinuation was lower in long-term SZC users compared to short-term SZC users (41.2 vs. 56.6%, p = 0.048). Short-term SZC treatment (≤90 days) was more frequent (83.1%) and predicted by dialysis (OR = 0.22). Healthcare costs over 6 months averaged €7,943 for short-term users (dialysis: €3,452) and €6,647 for long-term users (dialysis: €1,130).

CONCLUSIONS:

This real-world study showed that nearly 17% of patients continued SZC therapy for ≥90 days. Long-term therapy was associated with lower RAASi discontinuation and reduced healthcare costs due to hospitalizations and outpatient specialist services, suggesting that SZC can potentially provide clinical and economic benefits for HK management.

2025-12-01·Stress biology

Genetic characterization of the AHAS mutant line K4 with resistance to AHAS-inhibitor herbicides in rapeseed (Brassica napus L.)

Article

作者: Hu, Zhaoxin ; Huang, Qianxin ; Hu, Shengwu ; Guo, Yuan ; Gao, Lianliang ; Wang, Shengnan ; Qu, Gaoping ; Zhang, Yani

Abstract:

It remains a great challenge to control weeds in rapeseed fields in China. Breeding herbicide-resistant rapeseed varieties and using corresponding herbicide formulations has become the most economical and effective way to control weeds in rapeseed field. Characterization of more herbicide-resistant genetic resources will provide opportunities for breeders to develop rapeseed herbicide-resistant varieties with good agronomic performance. Previously, we obtained the tribenuron methyl (TBM)-resistant mutant K4 from ZS9 (Brassica napus L.) through ethyl methyl sulfonate mutagenesis and TBM foliar-spray screening. In this study, the inheritance and molecular characterization of the mutant K4 are carried out. Genetic investigation indicated that the herbicide-resistance of the K4 was controlled by one dominant allele at a single nuclear gene locus. Molecular characterization showed that a single point substitution at position 535 from C to T in BnAHAS3 (BnAHAS3535T), which resulted in a mutation at point 179 in BnAHAS3. The K4 showed a certain degree of resistance to TBM, bensulfuron methyl, and monosulfon sodium, which were 50, 30, and 5 times that of ZS9, respectively. AHAS enzyme assay, structural analysis of AHAS proteins, affinity detection between TBM and BnAHAS3 by surface plasmon resonance analysis, and the transgenic experiment in Arabidopsis using BnAHAS3535T confirmed that BnAHAS3535T endow the K4 with herbicides resistance. In addition, an allele-specific marker was developed to quickly distinguish the heterozygous and homozygous mutated alleles BnAHAS3535T. In conclusion, our research identified and characterized one novel mutative AHAS allele in B. napus and enriched genetic resource for developing herbicide-resistant rapeseed cultivars.

2025-08-01·Cardiovascular drugs and therapy

Hyperkalaemia in Cardiological Patients: New Solutions for an Old Problem

Review

作者: Abrignani, Maurizio Giuseppe ; Cesaro, Arturo ; Colivicchi, Furio ; Temporelli, Pier Luigi ; Gori, Mauro ; Riccio, Carmine ; Grimaldi, Massimo ; Maloberti, Alessandro ; Gronda, Edoardo ; Gabrielli, Domenico ; Marini, Marco ; Oliva, Fabrizio ; Binaghi, Giulio ; Iacoviello, Massimo ; Benvenuto, Manuela ; Tinti, Maria Denitza

Hyperkalaemia is one of the most common electrolyte disorders in patients with cardiovascular disease (CVD). The true burden of hyperkalaemia in the real-world setting can be difficult to assess, but in population-based cohort studies up to 4 in 10 patients developed hyperkalaemia. In addition to drugs interfering with potassium metabolism and food intake, several conditions can cause or worsen hyperkalaemia, such as advanced age, diabetes, and chronic kidney disease. Mortality, cardiovascular morbidity, and hospitalisation are higher in patients with hyperkalaemia. Hyperkalaemia represents a major contraindication or a withholding cause for disease-modifying therapies like renin-angiotensin-aldosterone inhibitors (RAASi), mainly mineralocorticoid receptor antagonists. Hyperkalaemia can be also classified as acute and chronic, according to the onset. Acute hyperkalaemia is often a life-threatening emergency requiring immediate treatment to avoid lethal arrhythmias. Therapy goal is cell membrane stabilisation by calcium administration, cellular intake, shift of extracellular potassium to the intracellular space (insulin, beta-adrenergic agents, sodium bicarbonate), and increased elimination with diuretics or dialysis. Chronic hyperkalaemia was often managed with dietary counselling to prevent potassium-rich food intake and tapering of potassium-increasing drugs, mostly RAASi. Sodium polystyrene sulphonate, a potassium binder, was the only therapeutic option. Recently, new drugs such as patiromer and sodium zirconium cyclosilicate give new opportunities for the treatment of hyperkalaemia, as they proved to be safe, well tolerated, and effective. Aim of this review is to describe the burden of hyperkalaemia in cardiovascular patients, its direct and indirect effects, and the therapeutic options now available in the acute and chronic setting.

73

项与环硅酸锆钠相关的新闻（医药）

2025-08-11

·药事纵横

阿斯利康"环硅酸锆钠散"遭遇专利围攻，正大天晴、先声药业、国为生物等多家企业发起专利无效挑战

一、基本信息阿斯利康的“环硅酸锆钠散”是一种口服降钾药物，用于治疗成人高钾血症。高钾血症是一种以血液中钾含量升高为特征的严重疾病，常发于晚期肾脏病和/或心力衰竭患者中。该药物于2019年12月获得中国CDE批准上市，结构示意图如下：分子式：Na~1.5H~0.5ZrSi3O9 • 2-3H2O 二、阿斯利康相关专利登记情况阿斯利康在中国上市药品专利信息登记平台上登记了3件核心专利，具体信息如下：信息分析及解读：专利信息 1（ZL201380055238.8）：该专利核心权利要求保护一种硅酸锆组合物，其包含式（I）的硅酸锆，ApMxZr1-xSinGeyO m（该式（I）包含了产品活性成份为环硅酸锆钠分子式），并限定组合物需包含ZS-9和ZS-7，且不含可检测量的ZS-8。对此，仿制药企业若想规避专利，可通过两种调整策略，一是对化学组成上进行调整，但技术难度较高（复杂仿制药与原研等效评价要求之一化学组成相同性）；二是将仿制药技术方案调整为组合物不包含“ZS-7”或者包含“可检测量的ZS-8”。 ZL201480072530.5（专利信息2）：该专利的核心权利要求与专利信息 1（ZL201380055238.8）同样保护硅酸锆组合物，但其要求组合物中至少95%为ZS-9，且不含特定X-射线衍射图谱的ZS-8。对此，仿制药企业若想规避该专利，规避设计需调整ZS-9含量或引入ZS-8，技术可行性尚不明确。 ZL201680059460.9（专利信息3）：该专利的核心权利要求保护一种阳离子交换组合物，具体限定了阳离子交换组合物的制备方法，技术特征较多，规避性较强。三、国内仿制企业注册申报及专利声明情况截止目前有4家仿制药注册申报了环硅酸锆钠散，同时对相应专利进行了声明，具体信息如下：专利声明类型：4.1类：中国上市药品专利信息登记平台收录的被仿制药品相关专利权应当被宣告无效，4.2类：仿制药未落入中国上市药品专利信息登记平台收录的被仿制药品相关专利权保护范围。分析及解读：从上述表格中可以看出多数企业通过规避设计绕开了ZL201680059460.9（专利信息3）的保护范围，但对ZL201380055238.8（专利信息 1）和ZL201480072530.5（专利信息2），部分企业选择请求宣告专利无效（4.1类），部分企业则声称已规避专利（4.2类）。这表明对于ZL201380055238.8（专利信息 1）和ZL201480072530.5（专利信息2）的规避可行性存在争议，不同企业采取了不同策略。四、专利无效情况分析及解读： ZL201480072530.5（专利信息2）的无效挑战热度高于ZL201380055238.8（专利信息 1），可能因其规避难度更大。部分企业（如正大天晴和成都国为生物）尚未提交该药品注册申请便对相关专利发起无效挑战，可能是为了提前评估专利稳定性或争取授权和解机会。首次无效失败决定要点简介： ZL201380055238.8（专利信息 1，第566397号无效决定）：涉案专利充分公开：合议组认定本领域技术人员基于涉案专利说明书中记载的内容能够制备得到相应的组合物，预期组合物具有降低血清K的作用，并且不含ZS-8能够减少对肾功能的影响。因此无效请求人认为涉案专利说明书不符合专利法第26条第3款（充分公开）的主张不能成立。 ZL201480072530.5（专利信息2，第584310号无效决定）：涉案专利的创造性：合议组认定涉案专利想要解决的技术问题为：提供有效治疗高钾血症同时减少尿液中锆水平以减轻肾损伤、以及降低醛固酮水平且避免副作用发生从而有助于治疗慢性肾病的ZS组合物。在面对这一技术问题时，证据2（WO2012109590A2）并未给出将组合物中ZS-9含量提升至至少95%且不包含ZS-8的区别特征引入证据2以获得涉案专利技术方案的技术启示。五、总结阿斯利康的“环硅酸锆钠散”在国内登记了三件专利，其中ZL201680059460.9（专利信息3）因规避性强，多数企业通过规避设计绕开其保护范围；而ZL201380055238.8（专利信息 1）和ZL201480072530.5（专利信息2）则成为仿制药企业的重点围攻目标，尤其是ZL201480072530.5（专利信息2），目前，已有正大天晴、先声药业、国为生物等多家企业发起专利无效宣告请求。尽管此前仿制药已经遭遇一次专利无效挑战失败，但阿斯利康能否像应对达格列净片专利挑战一样守住阵地，仍需拭目以待。药事纵横投稿须知：稿费已上调，欢迎投稿

专利无效上市批准专利到期

2025-07-25

·摩熵医药

10亿抗炎药首仿引角逐，恒瑞垄断时代或将落幕

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。7月24日，CDE官网显示，仁合益康集团有限公司按化药注册分类4类申报的艾瑞昔布片上市申请已获受理。据摩熵医药数据库显示，艾瑞昔布片2024年在我国院内市场销售额近10亿元，目前国内暂无仿制药获批，仁合益康大概率将斩获首仿。截图来源：CDE官网艾瑞昔布片是我国具有自主知识产权的第一个COX-2选择性抑制剂，属于非甾体消炎镇痛药（NSAIDs），用于缓解骨关节炎的疼痛症状。截图来源：摩熵医药全球药物研发数据库艾瑞昔布的研发始于1999年，2002年进入临床试验阶段，列入国家"863"计划。最终作为恒瑞医药研发的1.1类新药，于2011年5月获批上市，商品名”恒扬”。艾瑞昔布片获批上市后销售额稳步增长，市场迅速放量，并于2017年进入国家医保目录。据摩熵医药数据统计，2023年其院内销售额达到9.83亿元，较2022年的8.86亿元同比递增10.83%。其近两年销量显著提升，相信未来还有较大增长空间。截图来源：摩熵医药全国医院（全终端）销售数据库我国膝骨关节炎和类风湿性关节炎患者数量庞大，其关节肿胀、畸形及剧烈疼痛等症状，严重降低患者生活质量。当前我国抗炎和抗风湿药院内市场规模稳定在160亿元。截图来源：摩熵医药全国医院（全终端）销售数据库2024年度，艾瑞昔布片销售额达9.39亿元，跻身抗炎和抗风湿药销售榜单的TOP3 。截图来源：摩熵医药全国医院（全终端）销售数据库目前艾瑞昔布片尚未在国外上市，国内也暂无艾瑞昔布片仿制药获批。恒瑞医药独占市场14年之后，仁合益康作为国内首家提交仿制上市申请的企业，率先打破了原有的竞争格局，其拿下首仿获批的概率颇高。截图来源：摩熵医药中国药品审评数据库值得一提的是，艾瑞昔布的知识产权保护相当完善。其化合物专利已到期，但晶型专利将持续到2029年，制剂专利更是延续至2038年。这一系列分层延续的专利布局，为该药物的市场独占性提供了长期保障。在临床试验方面，除仁合益康外，南京优科制药的BE试验也正推进中，预计后续将有更多企业加入这一赛道布局。截图来源：摩熵医药中国临床试验数据库在仁合益康已上市的产品矩阵中，目前尚无抗炎抗风湿类药物，不过其按新注册分类申报的艾瑞昔布片、精氨酸布洛芬颗粒已进入审评阶段。截图来源：摩熵医药中国药品审评数据库今年以来，仁合益康已有16个仿制品种申报上市，覆盖神经系统药物、消化系统及代谢药、心脑血管系统药物等多个治疗领域。其中艾瑞昔布片、醋酸锌颗粒、口服用苯丁酸甘油酯、环硅酸锆钠散、阿仑膦酸钠口服溶液、注射用磷丙泊酚二钠等品种，目前国内均无仿制药获批。END本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-2025052024年医药企业综合实力排行榜-202505中国带状疱疹疫苗行业分析报告-2025052023H2-2024H1中国药品分析报告-202504数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-2025032024年中国1类新药靶点白皮书-202503中国AI医疗健康企业创新发展百强榜单-202502解码护肤抗衰：消费偏好洞察与市场格局分析-2025022024年FDA批准上市的新药分析报告-202501小分子化药白皮书（上）-2025012024年中国医疗健康投融资全景洞察报告-2025012024年医保谈判及市场分析报告-202501近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

专利到期上市批准

2025-07-24

·米内网

【关注】仁合益康入局10亿明星药

精彩内容7月24日，仁合益康2款仿制药西洛他唑片、艾瑞昔布片报产获受理。其中，艾瑞昔布片是一款抗炎抗风湿药，2024年在中国三大终端六大市场（统计范围详见本文末）的销售额超过10亿元，目前该药在国内暂无仿制药获批。艾瑞昔布片是一款非甾体抗炎药，通过抑制环氧酶（COX）发挥镇痛作用，用于缓解骨关节炎的疼痛症状。米内网数据显示，艾瑞昔布片为恒瑞医药开发的国产1类新药，目前已纳入国家医保乙类目录，2023年以来在中国三大终端六大市场的销售额呈逐年上涨态势，2024年超过10亿元，2025年第一季度接近2.5亿元。近年来中国三大终端六大市场艾瑞昔布片销售情况（单位：万元）来源：米内网格局数据库国内暂无艾瑞昔布片仿制药获批。仁合益康的产品于2025年7月24日以新注册分类报产，为国内首家，拿下首仿的几率较大。在仁合益康已上市产品中，暂无抗炎抗风湿药物，艾瑞昔布片、精氨酸布洛芬颗粒2个品种以新注册分类报产在审。米内网数据显示，近年来中国三大终端六大市场抗炎抗风湿药物（化药+生物药）销售额均超过200亿元。今年以来，仁合益康已有19个品种以新注册分类申报上市/临床，涉及神经系统药物、消化系统及代谢药、心脑血管系统药物等治疗大类。其中，艾瑞昔布片、醋酸锌颗粒、口服用苯丁酸甘油酯、环硅酸锆钠散、阿仑膦酸钠口服溶液、注射用磷丙泊酚二钠等均暂无国产仿制药获批。今年以来仁合益康以新分类申报的品种来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至7月24日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准

100 项与环硅酸锆钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10727	环硅酸锆钠	V03AE10	DB14048

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
高钾血症	欧盟	AstraZeneca AB	2018-03-22
高钾血症	冰岛	AstraZeneca AB	2018-03-22
高钾血症	列支敦士登	AstraZeneca AB	2018-03-22
高钾血症	挪威	AstraZeneca AB	2018-03-22

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心律失常	临床3期	美国	AstraZeneca PLC	2021-04-30
心律失常	临床3期	中国	AstraZeneca PLC	2021-04-30
心律失常	临床3期	日本	AstraZeneca PLC	2021-04-30
心律失常	临床3期	阿根廷	AstraZeneca PLC	2021-04-30
心律失常	临床3期	奥地利	AstraZeneca PLC	2021-04-30
心律失常	临床3期	巴西	AstraZeneca PLC	2021-04-30
心律失常	临床3期	保加利亚	AstraZeneca PLC	2021-04-30
心律失常	临床3期	加拿大	AstraZeneca PLC	2021-04-30
心律失常	临床3期	捷克	AstraZeneca PLC	2021-04-30
心律失常	临床3期	德国	AstraZeneca PLC	2021-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04676646 (REALIZE-K, CTgov)	临床4期	射血分数降低的心力衰竭 \| 高钾血症	366	Placebo+Spironolactone+Sodium zirconium cyclosilicate	壓簾繭窪繭鑰餘淵簾網(繭鏇繭遞壓網構衊構顧) = 獵顧獵憲願餘鹹淵膚襯廠齋憲觸觸繭淵積製壓 (憲構製餘積築襯醖糧積, 築選鹽構鑰夢鏇鹹觸膚 ~ 繭範憲鹽選範顧範鬱獵) 更多	-	2025-07-09
NCT04847232 (CTgov)	临床3期	心律失常 \| 高钾血症	2,690	SZC Placebo	繭艱獵繭網製醖範醖願 = 構獵構範襯淵積襯醖壓鑰願齋糧鬱製簾餘鬱遞 (簾糧鹽憲齋鑰襯齋鬱窪, 蓋獵積繭願齋築選鑰齋 ~ 獵醖襯製艱廠積淵獵鹽) 更多	-	2025-06-18
NCT04983979 (ORTIZ, CTgov)	临床2期	2型糖尿病 \| 糖尿病肾病 \| 慢性肾病 ... 更多	18	Placebo	醖蓋獵醖醖遞醖淵艱廠(夢鑰醖範觸廠鑰鑰壓觸) = 觸簾窪選鏇襯築膚鬱餘蓋餘積憲蓋襯醖願鹽製 (廠鹹構膚範窪築壓夢鹽, 0.42) 更多	-	2025-06-08
NCT06029179 (Pubmed \| BMC Nephrol)	N/A	高钾血症	120	Sodium zirconium cyclosilicate (SZC)	獵艱糧網廠蓋製範鹽簾(醖鑰範淵繭選夢構遞窪) = 鑰觸廠範積膚鹹廠構遞選窪繭廠構顧顧構選鏇 (築鏇廠網窪鑰製蓋遞齋 )	积极	2025-05-06
				Sodium polystyrene sulfonate (SPS)	獵艱糧網廠蓋製範鹽簾(醖鑰範淵繭選夢構遞窪) = 糧觸襯廠獵簾憲齋顧選選窪繭廠構顧顧構選鏇 (築鏇廠網窪鑰製蓋遞齋 )
NCT04676646 (REALIZE-K, Literature) 人工标引	临床4期	心脏衰竭 \| 高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	襯遞鑰鬱憲襯齋簾廠鬱(範繭齋鏇糧鹽廠糧網鬱) = 觸鹽鬱蓋鏇顧鬱積鹹廠鹹餘窪網獵築遞鏇製製 (餘淵繭簾鏇窪網鏇構製 ) 更多	积极	2024-11-18
				Placebo	襯遞鑰鬱憲襯齋簾廠鬱(範繭齋鏇糧鹽廠糧網鬱) = 齋獵糧蓋築夢艱憲範選鹹餘窪網獵築遞鏇製製 (餘淵繭簾鏇窪網鏇構製 ) 更多
GALVANIZE (AHA2024) 人工标引	N/A	高钾血症	-	Sodium zirconium cyclosilicate (long-term)	襯鬱繭膚繭選廠範鬱鏇(廠醖糧襯鏇築壓觸構鑰) = 構網窪餘鬱顧繭淵淵憲鏇齋齋鹹蓋繭鑰蓋鹹製 (鹹餘窪繭鏇醖積鹽夢網 ) 更多	积极	2024-11-11
				Sodium zirconium cyclosilicate (short-term)	襯鬱繭膚繭選廠範鬱鏇(廠醖糧襯鏇築壓觸構鑰) = 網鹹製廠鏇製製製夢繭鏇齋齋鹹蓋繭鑰蓋鹹製 (鹹餘窪繭鏇醖積鹽夢網 ) 更多
NCT04676646 (REALIZE-K, Pubmed \| J Am Coll Cardiol)	临床4期	高钾血症	203	Sodium Zirconium Cyclosilicate (SZC)	製壓繭廠壓蓋襯積壓簾(壓憲選積鬱糧鬱遞艱夢) = 簾膚鏇鏇鹹鬱淵夢糧鏇窪鹽鹹願糧顧範蓋願鑰 (糧衊範夢願網獵艱觸顧 )	积极	2024-11-01
				Placebo	製壓繭廠壓蓋襯積壓簾(壓憲選積鬱糧鬱遞艱夢) = 製糧鬱夢壓蓋襯網簾遞窪鹽鹹願糧顧範蓋願鑰 (糧衊範夢願網獵艱觸顧 )
NCT03528681 (HARMONIZE Asia, Pubmed \| Clin Ther)	临床3期	高钾血症	270	Sodium Zirconium Cyclosilicate 5g	鬱獵鏇齋築顧製築糧糧(餘顧獵齋積獵願鏇壓齋) = driven primarily by peripheral edema and constipation 廠糧願憲醖壓夢繭簾積 (鑰窪積觸遞構鏇顧齋膚 )	积极	2024-08-06
				Sodium Zirconium Cyclosilicate 10g
NCT04207203 (Pubmed \| Am J Clin Nutr)	N/A	慢性肾病	26	sodium zirconium cyclosilicate (Low-protein low-potassium diet + SZC)	繭齋廠夢膚廠積範淵願(糧鏇蓋積壓鬱醖鏇積觸) = 衊簾築網網獵憲繭膚衊廠選膚範簾窪糧餘窪餘 (鏇顧鹽積衊願繭構鏇網 ) 更多	积极	2024-07-01
				sodium zirconium cyclosilicateSZCsilicate (Plant-based diet + SZC)	繭齋廠夢膚廠積範淵願(糧鏇蓋積壓鬱醖鏇積觸) = 觸蓋觸願餘襯鏇糧衊醖廠選膚範簾窪糧餘窪餘 (鏇顧鹽積衊願繭構鏇網 ) 更多
NCT04676646 (REALIZE-K, Pubmed \| JACC Heart Fail)	临床4期	高钾血症	365	Sodium Zirconium Cyclosilicate (SZC)	蓋鬱餘淵遞壓顧襯憲夢(製願廠醖齋壓鬱遞選淵) = 淵顧窪範糧鑰鏇窪艱觸壓鏇餘鹽夢憲選鑰艱繭 (構醖餘遞壓遞鹹壓壓憲 ) 更多	积极	2024-05-13